Clinical Trial Update: A Study of Erlotinib (Tarceva) Versus Gemcitabine/Cisplatin as First-line Treatment in Patients With Non-small Cell Lung Cancer With EGFR Mutations [Phase 3]

View source ↗

Summary

Phase 3 trial comparing erlotinib (Tarceva) to gemcitabine/cisplatin as first-line treatment in EGFR-mutant non-small cell lung cancer completed with results po…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• CISPLATIN (cisplatin)
• Gemzar (gemcitabine)
• Tarceva (erlotinib)

Snippet

Sponsor: Hoffmann-La Roche | Conditions: Non-Small Cell Lung Cancer | Phase 3 | Status: COMPLETED | Results posted: 2015-02-24